News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
693,365 Results
Type
Article (39857)
Company Profile (314)
Press Release (653194)
Section
Business (205419)
Career Advice (2023)
Deals (35579)
Drug Delivery (93)
Drug Development (81306)
Employer Resources (169)
FDA (16157)
Job Trends (14882)
News (347161)
Policy (33083)
Tag
Academia (2568)
Alliances (49708)
Alzheimer's disease (1276)
Approvals (16120)
Artificial intelligence (145)
Bankruptcy (354)
Best Places to Work (11628)
Biotechnology (221)
Breast cancer (191)
Cancer (1381)
Cardiovascular disease (110)
Career advice (1689)
Cell therapy (285)
Clinical research (65004)
Collaboration (491)
Compensation (264)
COVID-19 (2584)
C-suite (110)
Data (1399)
Diabetes (179)
Diagnostics (6209)
Earnings (85162)
Employer resources (147)
Events (111079)
Executive appointments (401)
FDA (16849)
Funding (437)
Gene therapy (196)
GLP-1 (604)
Government (4627)
Healthcare (18843)
Infectious disease (2677)
Inflammatory bowel disease (115)
Interviews (311)
IPO (16403)
Job creations (3663)
Job search strategy (1443)
Layoffs (423)
Legal (7969)
Lung cancer (199)
Manufacturing (209)
Medical device (13242)
Medtech (13247)
Mergers & acquisitions (19346)
Metabolic disorders (464)
Neuroscience (1602)
NextGen Class of 2024 (6549)
Non-profit (4506)
Northern California (1711)
Obesity (262)
Opinion (189)
Parkinson's disease (98)
Patents (121)
People (57013)
Phase I (20260)
Phase II (28632)
Phase III (21327)
Pipeline (514)
Postmarket research (2565)
Preclinical (8610)
Radiopharmaceuticals (237)
Rare diseases (264)
Real estate (5963)
Regulatory (21935)
Research institute (2332)
Resumes & cover letters (350)
Southern California (1483)
Startups (3633)
United States (15338)
Vaccines (569)
Weight loss (183)
Date
Today (3)
Last 7 days (382)
Last 30 days (2290)
Last 365 days (35496)
2024 (35367)
2023 (40286)
2022 (51385)
2021 (55966)
2020 (54320)
2019 (46947)
2018 (35366)
2017 (32334)
2016 (31747)
2015 (37798)
2014 (31541)
2013 (26605)
2012 (28833)
2011 (29522)
2010 (27594)
Location
Africa (720)
Arizona (196)
Asia (37720)
Australia (6156)
California (3869)
Canada (1468)
China (312)
Colorado (174)
Connecticut (178)
Europe (80857)
Florida (538)
Georgia (136)
Illinois (392)
Indiana (226)
Maryland (636)
Massachusetts (2992)
Michigan (175)
Minnesota (292)
New Jersey (1111)
New York (1097)
North Carolina (747)
Northern California (1711)
Ohio (148)
Pennsylvania (932)
South America (1099)
Southern California (1483)
Texas (562)
Utah (108)
Washington State (402)
693,365 Results for "cn biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
Harmony Biosciences, announced the acquisition of Epygenix Therapeutics, Inc., accelerating its growth strategy by adding a rare epilepsy franchise to its expanding late-stage pipeline of innovative CNS assets.
April 30, 2024
·
9 min read
Drug Development
Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models.
June 5, 2024
·
5 min read
Genetown
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 InhibitorIND-enabling studies expected to begin mid-2024
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program.
April 9, 2024
·
4 min read
Business
CNS Pharmaceuticals Reports First Quarter 2024 Financial Results
CNS Pharmaceuticals, Inc. today reported its financial results for the first quarter 2024 ended March 31, 2024.
May 16, 2024
·
5 min read
Lone Star Bio
CNS Pharmaceuticals to Present at the LSX World Congress 2024
CNS Pharmaceuticals, Inc. announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the LSX World Congress 2024 on Monday, April 29, 2024 at 4:15 PM in London, England.
April 23, 2024
·
2 min read
Lone Star Bio
CNS Pharmaceuticals to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
CNS Pharmaceuticals, Inc. today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024 at 1:40 PM ET.
May 20, 2024
·
1 min read
Deals
CNS Pharmaceuticals Announces Reverse Stock Split - June 4, 2024
CNS Pharmaceuticals, Inc. today announced a 1-for-50 reverse split of its common stock, effective at 4:01 PM ET on June 4, 2024.
June 3, 2024
·
3 min read
Press Releases
CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 15, 2024
·
6 min read
Press Releases
Bionomics to Present at the 2024 CNS Summit
November 8, 2024
·
3 min read
Biotech Bay
Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays
Alamar Biosciences announced today the commercial launch of the NULISAseq CNS Disease Panel 120 for highly multiplexed protein analysis of all the critical pathways implicated in major neurological disorders, and the NULISAqpcr pTau-217 Assay
March 5, 2024
·
3 min read
1 of 69,337
Next
